Interestingly, all three types of tumor harboring wild type EGFR or EGFR mutations showed increased PD-L1 promoter methylation and also decreased PD-L1 mRNA level after anti-PD-1 therapy (Figure 3C, 3D; Supplementary Figure 2). This evidence concerns the gene CD274 and neoplasm.